With 0.18 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.25 million shares. During the session, the Medical Care Facilities company that operates in wider Healthcare sector, reached to the highest price of $89.9899 whereas the lowest price it dropped to was $82.99. The 52-week range on NUTX shows that it touched its highest point at $184.27 and its lowest point at $17.51 during that stretch. It currently has a 1-year price target of $241.67. Beta for the stock currently stands at -0.17.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of NUTX was down-trending over the past week, with a drop of -9.32%, but this was down by -1.20% over a month. Three-month performance dropped to -50.05% while six-month performance rose 52.62%. The stock gained 164.41% in the past year, while it has gained 256.40% so far this year. A look at the trailing 12-month EPS for NUTX yields 11.90 with Next year EPS estimates of 11.86. For the next quarter, that number is 0.62. This implies an EPS growth rate of -44.97% for this year and 121.96% for next year.
Float and Shares Shorts:
At present, 5.53 million NUTX shares are outstanding with a float of 3.54 million shares on hand for trading. On 2025-08-15, short shares totaled 0.89 million, which was 1605.9999 higher than short shares on 1752537600. In addition to Dr. Thomas T. Vo M.B.A., M.D. as the firm’s Chairman of the Board & CEO, Dr. Warren Hosseinion M.D. serves as its President & Director.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, NUTX reported revenue of $211789000.0 and operating income of $72209000.0. The EBITDA in the recently reported quarter was $73976000.0 and diluted EPS was $2.56.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for NUTX since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With NUTX analysts setting a high price target of 300.0 and a low target of 205.0, the average target price over the next 12 months is 241.66667. Based on these targets, NUTX could surge 258.04% to reach the target high and rise by 144.66% to reach the target low. Reaching the average price target will result in a growth of 188.42% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$1.89558 being high and -$2.15108 being low. For NUTX, this leads to a yearly average estimate of -$2.02333. The surprise factor in the prior quarter was -$0.12. Based on analyst estimates, the high estimate for the next quarter is $1.95 and the low estimate is $1.95. The average estimate for the next quarter is thus $1.95.
